FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients

Thumbnail
2014
2067.pdf (1.280Mb)
Authors
Mirjanić-Azarić, Bosa
Vekić, Jelena
Zeljković, Aleksandra
Jelić-Ivanović, Zorana
Đerić, Mirjana
Milivojac, Tatjana
Fonović, Ursa Pecar
Marc, Janja
Kos, Janko
Cerne, Darko
Article (Published version)
Metadata
Show full item record
Abstract
Aim: We hypothesized that, in stable angina patients, atorvastatin therapy lowers the cathepsin S (CTSS) concentrations, as assessed non-invasively according to a plasma analysis. In addition, the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) size and subclasses in the plasma were analysed to establish the association between CTSS and lipoprotein metabolism and determine whether this association is atorvastatin-sensitive. Methods: A total of 43 patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). The plasma CTSS mRNA levels, CTSS protein concentrations and CTSS activity, as well as LDL and HDL size and subclasses, were analysed before and after treatment. Results: Atorvastatin treatment did not change the plasma CTSS mRNA levels, although it lowered the plasma CTSS concentrations and activity. An increased plasma CTSS concentration and activity were found to be associated with a more atherogenic LDL subclass profile (a decreased dominant L...DL size and increased percentage of small, dense LDL particles). The atorvastatin-induced CTSS-lowering effect was concomitant with an improvement in the LDL subclass profile, and the changes were found to be interrelated. Concomitant, interrelated changes in the CTSS levels and LDL subclass profiles were found in the LDL phenotype B patients only (a dominant LDL diameter of lt = 25.5 nm at the start of the study). In this subgroup, lowering of the plasma CTSS mRNA level also correlated with lowering of the proportion of small, dense LDL particles. Conclusions: Atorvastatin-induced CTSS-lowering and LDL subclass profile improvements in the plasma of LDL phenotype B patients with stable angina are concomitant and interrelated.

Keywords:
Atorvastatin / Cathepsin S / LDL subclasses / LDL phenotype
Source:
Journal of Atherosclerosis and Thrombosis, 2014, 21, 8, 868-877
Publisher:
  • Japan Atherosclerosis Soc, Tokyo
Projects:
  • Ad Futura - Scientific and Educational Foundation of the Republic of Slovenia, the Slovenian Research Agency, Republic of Slovenia grant P4-0127

DOI: 10.5551/jat.21410

ISSN: 1340-3478

PubMed: 24727728

WoS: 000342071100009

Scopus: 2-s2.0-84906810476
[ Google Scholar ]
6
7
URI
http://farfar.pharmacy.bg.ac.rs/handle/123456789/2069
Collections
  • Radovi istraživača / Researchers’ publications
Institution
Pharmacy

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB